Sinopharm Group Co. Ltd (X2S) — Cash Flow Quality Index
Sinopharm Group Co. Ltd (X2S) has a Cash Flow Quality Index of -1.05x as of June 2023. Operating cash flow of €-2.63 Billion is below net income of €2.51 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Sinopharm Group Co. Ltd (X2S) long-term investment share to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinopharm Group Co. Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Sinopharm Group Co. Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sinopharm Group Co. Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year earnings quality comparison for Sinopharm Group Co. Ltd. For live market cap and the full company financial profile, see market cap of Sinopharm Group Co. Ltd.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.98x | €14.14 Billion | €7.16 Billion | ▲ +20.6% |
| 2024 | 1.64x | €11.55 Billion | €7.05 Billion | ▼ -13.7% |
| 2023 | 1.90x | €17.17 Billion | €9.05 Billion | ▼ -22.9% |
| 2022 | 2.46x | €20.96 Billion | €8.53 Billion | ▲ +105.0% |
| 2021 | 1.20x | €9.31 Billion | €7.76 Billion | ▼ -22.7% |
| 2020 | 1.55x | €11.15 Billion | €7.19 Billion | ▼ -48.3% |
| 2019 | 3.00x | €18.78 Billion | €6.25 Billion | ▲ +379.7% |
| 2018 | 0.63x | €3.65 Billion | €5.84 Billion | ▲ +8.8% |
| 2017 | 0.58x | €3.21 Billion | €5.58 Billion | ▼ -71.1% |
| 2016 | 1.99x | €9.26 Billion | €4.65 Billion | ▼ -44.0% |
| 2015 | 3.56x | €13.41 Billion | €3.77 Billion | ▲ +83.8% |
| 2014 | 1.93x | €5.56 Billion | €2.87 Billion | ▼ -11.9% |
| 2013 | 2.20x | €4.94 Billion | €2.25 Billion | — |